Viral Vector Upstream Platforms
Optimizing the upstream portion of gene therapy production sets the stage for successful manufacturing by maximizing viral vector titers. To increase upstream titers and reduce variability and risk, manufacturers must partner with upstream technology experts who work with HEK293, HEK293T, and Sf9 cells. Draw on our experience today to speed your gene therapy to patients. Learn more.
In recent years, the biopharma industry has been anything but predictable. But the creation of the Inflation Reduction Act (IRA) of 2022 has added a new layer of uncertainty that reaches most corners of the industry.
See the answer from Stephen Rapundalo, president and CEO of MichBio.
While in my last corporate job at a Fortune 100 company, I realized the kind of leader I would be: I would be me — authentic, kind, collaborative, purpose-driven, and empowering.
There was a general sentiment among the PBMs that, at least in the beginning, Humira would remain in a preferred position alongside some combination of biosimilars. It is likely the ambiguity was intentional to encourage further competition among the new entrants.
How mRNA Manufacturers Disrupt The Industry
Learn how biopharmaceutical companies can apply proven strategies to overcome the hidden complexities in mRNA production. Discover solutions that can help you rapidly design and build a SU facility.
CONTRIBUTE TO LIFE SCIENCE LEADER
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
|Connect With Life Science Leader:|